Areas of Expertise:
Acute myeloid leukemia, Novel therapies
Locations: Main Campus
Dr. Richard Aplenc is a Professor of Pediatrics in the Department of Pediatrics and a core faculty member of the Center for Pediatric Clinical Effectiveness at CHOP. Dr. Aplenc’s research focuses on improving the outcomes of children with cancer, particularly acute myeloid leukemia (AML.) His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions. Dr. Aplenc has NIH funded research efforts in pediatric AML focused on determining the genetic predictors of treatment response (specifically relapse and infection risk) and using administrative/billing data to augment NCI funded cooperative oncology group clinical trials. He is currently leading a genome-wide genotyping effort to discover genetic variations that change the risks of relapse, life-threatening infections, and heart complications in children treated for AML. He also leads several efforts to use administrative data sets to improve the care of children with AML, particularly focusing on antibiotic and intensive care use.
Dr. Aplenc leads a large, Phase III trial for children with acute myeloid leukemia in the Children’s Oncology Group and serves as the Vice-Chair of the COG AML Committee. In addition to this work, Dr. Aplenc also leads Phase I trials for children whose cancers have not responded to standard therapy. These trials include gemtuzumab, dasatinib and obatoclax. He is the Primary Investigator at Children’s Hospital of Philadelphia for multiple Phase I trials that are offered through the Children’s Oncology Group and he helps lead the Hematologic Malignancies Program and Experimental Therapeutics Program here at CHOP.
The Children's Hospital of Philadelphia has a long tradition of embracing the total care of patients and their families. Every child receiving complex cancer therapy needs the expertise of more than one provider. That is why Dr. Aplenc works with other CHOP physicians, nurses and social workers to provide a team approach to total care. This kind of collaboration with the family and patient helps provide the best, most modern and sophisticated care — not only nationally, but in the world.
Education and Training
University of Virginia School of Medicine (MD)
The Children's Hospital of Philadelphia, Philadelphia, Pa.
American Board of Pediatrics/Hematology-Oncology
University of California, San Diego. Calif.
Master of Science in Clinical Epidemiology, University of Pennsylvania (MS)
Titles and Academic Titles
Assistant Vice President and Chief Clinical Research Officer
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Departments and Services
- Cancer Center
- Leukemia and Lymphoma Program
- Center for Pediatric Clinical Effectiveness (CPCE)
- Cancer Immunotherapy Program
- Department of Biomedical and Health Informatics (DBHi)
Areas of Focus
- Treatment of Pediatric Acute Myeloid Leukemia (AML) with Chimeric Antigen Receptor (CAR) T-cells
- Clinical Evaluation of Antibody-drug Conjugates and Targeted Cancer Agents for Acute Myeloid Leukemia (AML)
Laboratories & Research Programs
Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report. Blood. 2017;129(23):3051-3058.
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Oct;62(10):1775-81.
Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Med. 2015 Sep;4(9):1356-64.
Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jul;62(7):1184-9.
G Salazar E, Bernhardt MB, Li Y, Aplenc R, Adamson PC. The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jun;62(6):940-4.
Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, Bagatell R, Fisher BT, Aplenc R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2015 Apr;62(4):704-9.
Cantu E, Shah RJ, Lin W, Daye ZJ, Diamond JM, Suzuki Y, Ellis JH, Borders CF, Andah GA, Beduhn B, Meyer NJ, Ruschefski M, Aplenc R, Feng R, Christie JD; Lung Transplant Outcomes Group Investigators. Oxidant stress regulatory genetic variation in recipients and donors contributes to risk of primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2015 Feb;149(2):596-602.
Wray L, Vujkovic M, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R. TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Nov;61(11):2086-8.
Freedman JL, Faerber J, Kang TI, Dai D, Fisher BT, Huang YS, Li Y, Aplenc R, Feudtner C. Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2014 Oct;61(10):1798-805.
Goodman EK, Reilly AF, Fisher BT, Fitzgerald J, Li Y, Seif AE, Huang YS, Bagatell R, Aplenc R. Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals. JAMA Pediatr. 2014 Oct;168(10):925-31.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17.
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014 Sep 20;32(27):3021-32.
Desai AV, Kavcic M, Huang YS, Herbst N, Fisher BT, Seif AE, Li Y, Hennessy S, Aplenc R, Bagatell R. Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database. Pediatr Blood Cancer. 2014 Jun;61(6):1129-31.
Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N; Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014 May 29;123(22):3504-11.
Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YS, Harris T, Shah A, Hall M, Fieldston ES, Kavcic M, Vujkovic M, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker DM, Aplenc R. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014 May;61(5):846-52.
Oshrine BR, Olsen MN, Heneghan M, Wertheim G, Daber R, Wilmoth DM, Biegel JA, Pawel B, Aplenc R, King RL. Acquired isochromosome 12p, somatic TP53 and PTEN mutations, and a germline ATM variant in an adolescent male with concurrent acute megakaryoblastic leukemia and mediastinal germ cell tumor. Cancer Genet. 2014 Apr;207(4):153-9.
Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YS, Zaoutis T, Torp K, Leckerman KH, Aplenc R. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clin Infect Dis. 2014 Feb;58(4):502-8.
Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc R. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med. 2014 Feb;15(2):112-20.http://www.ncbi.nlm.nih.gov/pubmed/24366507
Fisher BT, Singh S, Huang YS, Li Y, Gregory J, Walker D, Seif AE, Kavcic M, Aplenc R. Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatr Blood Cancer. 2014 Jan;61(1):68-73.
Lothstein K, Fisher B, Li Y, Seif A, Harris T, Torp K, Kavcic M, Huang YS, Rheingold SR, Aplenc R. Zoonotic infections in pediatric patients with acute leukemia. Pediatr Blood Cancer. 2013 Dec;60(12):E160-2.
de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr. 2013 Sep;163(3):699-705.
Johnston DL, Nagarajan R, Caparas M, Schulte F, Cullen P, Aplenc R, Sung L. Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. PLoS One. 2013 Sep 6;8(9):e74549.
Fisher BT, Gerber JS, Leckerman KH, Seif AE, Huang YS, Li Y, Harris T, Torp K, Douglas R, Shah A, Walker D, Aplenc R. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leuk Lymphoma. 2013 Aug;54(8):1633-9.
Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, Aplenc R. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr. 2013 Jun;162(6):1252-8, 1258.e1.
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Blood. 2013 Jun 27;121(26):5154-7.
Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, Bagatell R, Aplenc R. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer. 2013 May 15;119(10):1916-23.
Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013 May;60(5):728-33.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-18.
Walker DM, Fisher BT, Seif AE, Huang YS, Torp K, Li Y, Aplenc R. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer. 2013 Apr;60(4):616-20.
Kavcic M, Fisher BT, Torp K, Li Y, Huang YS, Seif AE, Vujkovic M, Aplenc R. Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatr Blood Cancer. 2013 Mar;60(3):508-11.
Kang TI, Hexem K, Localio R, Aplenc R, Feudtner C. The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists. Pediatr Blood Cancer. 2013 Jan;60(1):88-94.
Editorial and Academic Positions
2009-present, Biology of Blood and Marrow Transplantation
2009-present, Journal of the American Medical Association
2007-present, People Living With Cancer (PLWC.org), Editorial Board Member
2007-present, Cancer Research
2005-present, Bone Marrow Transplant
2005-present, Annals of Hematology
2005-present, American Journal of Epidemiology
2004-present, Journal of Clinical Oncology
2004-present, Journal of the National Cancer Institute
2003-present, Cancer Epidemiology, Biomarkers and Prevention
2003-present, International Journal of Cancer
2003-present, Pediatric Blood and Cancer
2002-present, Clinical Cancer Research
2001-present, Medical and Pediatric Oncology
2001-present, Journal of Pediatric Hematology-Oncology
2009-present, Clinical Research Quality Assurance Committee
2007-present, Hematopoietic Malignancies Clinical Steering Committee
2003-present, Certificate Program Working Group, Center for Clinical Epidemiology and Biostatistics
1999-present, Institutional Review Board, The Children's Hospital of Philadelphia
Leadership and Memberships
CHOP Clinical Trials Research Affinity Group, Advisory committee member
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.